3 India's Largest Pharma Company, Complex Generics and Oncology Specialist and Branded Generics Maker Stocks With a Strong Future Roadmap: Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals

Branded generic and oncology drug stocks let investors follow companies that serve a growing part of the Indian economy. Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals cover India's largest pharma company by market value, a complex generics and oncology specialist and a branded generics maker.

This list covers three branded generic and oncology drug stocks with complete current figures: Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Branded Generic and Oncology Drug Stocks?

Branded generic and oncology drug stocks are listed companies that sell branded medicines at home and abroad, develop complex generics and cancer treatments, and supply branded generics to doctors and chemists. Their earnings depend on prescriptions, product launches and approvals.

Branded Generic and Oncology Drug Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing branded generic and oncology drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Branded Generic and Oncology Drug Stocks Have a Strong Roadmap in India?

Branded generic and oncology drug stocks have a strong roadmap in India because an ageing population, wider insurance cover and new complex product launches keep widening the market for these medicine makers.

• Rising prescriptions. Chronic care needs lift steady medicine demand.
• Complex products. Harder to make drugs support better earnings quality.
• Wide reach. Doctor and chemist networks help repeat sales.

Why Sun Pharma Features Among These Branded Generic and Oncology Drug Stocks

Among the branded generic and oncology drug stocks on this list, Sun Pharmaceutical Industries is India's largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.

Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%.

In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.

Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What to watch: Track specialty product launches, United States approvals and domestic prescription trends.

Why Natco Pharma Features Among These Branded Generic and Oncology Drug Stocks

Among the pharma leader shares on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Why Lincoln Pharmaceuticals Features Among These Branded Generic and Oncology Drug Stocks

Among the three companies on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.

The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.

Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore.

Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What to watch: Track branded product growth, export orders and new launches.

Sun Pharma vs Natco Pharma vs Lincoln Pharmaceuticals on Key Financials

The table below sets the three branded generic and oncology drug stocks side by side on revenue, profit and margin, using reported figures.

Natco Pharma posts the highest return on equity in this group at 15.4%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with branded generic and oncology drug stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Branded Generic and Oncology Drug Stocks

Every theme carries risks that deserve a check before any decision. For these branded generic and oncology drug stocks, the main points are: Long-term pharma leader shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter branded generic and oncology drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Branded Generic and Oncology Drug Stocks

Branded generic and oncology drug stocks reward investors who follow demand trends, order books and margins together. Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals each have a clear plan to grow. Based on the 29 October 2026 close, Sun Pharma trades at Rs 1,761, Natco Pharma at Rs 787.55 and Lincoln Pharmaceuticals at Rs 509.9.

Download the Univest iOS App or Univest Android App to track branded generic and oncology drug stocks, set price alerts and get research-backed stock ideas.

What are branded generic and oncology drug stocks?

Ans. Branded generic and oncology drug stocks are listed companies that sell branded medicines at home and abroad, develop complex generics and cancer treatments, and supply branded generics to doctors and chemists. Their earnings depend on prescriptions, product launches and approvals. This list looks at three of them, Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which branded generic and oncology drug stocks are covered in this list?

Ans. This list covers Sun Pharma, Natco Pharma and Lincoln Pharmaceuticals. Based on the 29 October 2026 close, Sun Pharma traded at Rs 1,761, Natco Pharma at Rs 787.55 and Lincoln Pharmaceuticals at Rs 509.9. Their return on equity ranges from 11.6% to 15.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 21.0%.

Why do branded generic and oncology drug stocks have a strong future roadmap in India?

Ans. Branded generic and oncology drug stocks have a strong roadmap in India because an ageing population, wider insurance cover and new complex product launches keep widening the market for these medicine makers. The main drivers are as follows. Rising prescriptions. Chronic care needs lift steady medicine demand. Complex products. Harder to make drugs support better earnings quality. Wide reach. Doctor and chemist networks help repeat sales. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sun Pharma performed financially?

Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

How has Lincoln Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What risks should investors check before buying branded generic and oncology drug stocks?

Ans. Investors should check a few risks before buying branded generic and oncology drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of branded generic and oncology drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.